Optimizing the dosing regimens for intravascular administrations of oncolytic adenovirus

被引：0

作者：

Tsai, V ^{[1
]}

Johnson, DE ^{[1
]}

Schluep, T ^{[1
]}

Quijano, E ^{[1
]}

Wen, SF ^{[1
]}

Ralston, R ^{[1
]}

Demers, GW ^{[1
]}

Ramachandra, M ^{[1
]}

机构：

[1] Canji Inc, San Diego, CA USA

来源：

IMMUNOLOGY 2004: GENOMIC ISSUES, IMMUNE SYSTEM ACTIVATION AND ALLERGY | 2004年

关键词：

D O I：

暂无

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The objective of this study was to determine the impact of multiple-dose regimens on the activity of the final dose of an oncolytic adenovirus. Groups of tumor-bearing mice were dosed with the oncolytic adenovirus 01/PEME on each of 1, 2, 3, or 4 consecutive days prior to final treatment with a single dose of a different oncolytic adenovirus carrying the reporter gene, dl01/07-luc. Delivery and replication of the dl01/07-luc in the tumor and liver were determined by quantifying virus DNA copies by PCR and reporter gene activity by a luciferase enzymatic assay. Our results showed that there was a regimen-dependent effect after multiple prior intravenous administrations on the biological activity of dl01/07-luc.

引用

页码：429 / 436

页数：8

共 50 条

[41] Optimizing ganciclovir and valganciclovir dosing regimens in pediatric patients with cytomegalovirus infection: a spotlight on therapeutic drug monitoring
Li, Qiu-Yue
van den Anker, John
Wu, Yue-E
Hao, Guo-Xiang
Zhao, Wei
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2023, 16 (08) : 727 - 739
[42] Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: A sub-analysis of tolerability and cytokine data from the EVOLVE study of enadenotucirev (EnAd), an oncolytic adenovirus
McElwaine-Johnn, H.
Pover, G.
Alvis, S.
Brown, R.
Fisher, K.
Morris, C.
Champion, B.
Beadle, J.
ANNALS OF ONCOLOGY, 2017, 28 : 14 - 14
[43] Replicative oncolytic adenoviruses in multimodal cancer regimens
Post, DE
Khuri, FR
Simons, JW
Van Meir, EG
HUMAN GENE THERAPY, 2003, 14 (10) : 933 - 946
[44] Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications
Uusi-Kerttula, Hanni
Hulin-Curtis, Sarah
Davies, James
Parker, Alan L.
VIRUSES-BASEL, 2015, 7 (11): : 6009 - 6042
[45] Oncolytic immunotherapy with PD-1 blockade and telomerasespecific oncolytic adenovirus in osteosarcoma
Demiya, Koji
Tazawa, Hiroshi
Mochizuki, Yusuke
Kure, Miho
Hasei, Joe
Kunisada, Toshiyuki
Urata, Yasuo
Ozaki, Toshifumi
Fujiwara, Toshiyoshi
CANCER RESEARCH, 2019, 79 (13)
[46] Optimizing Maternal and Fetal Antibody Exposure and Dosing Regimens During Pregnancy Using a Physiologically Based Pharmacokinetic Model
Kardouh, Miramar Sami
Dunlap, Tyler C.
Zhong, Rui
Tiley, Jacqueline B.
Cao, Yanguang
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2025,
[47] Antimalarial dosing regimens and drug resistance
Barnes, Karen I.
Watkins, William M.
White, Nicholas J.
TRENDS IN PARASITOLOGY, 2008, 24 (03) : 127 - 134
[48] Temozolomide Dosing Regimens for Glioma Patients
Herwig M. Strik
Christine Marosi
Bernd Kaina
Bart Neyns
Current Neurology and Neuroscience Reports, 2012, 12 : 286 - 293
[49] DOSING REGIMENS IN SERIOUSLY ILL PATIENTS
SPECTOR, R
JOURNAL OF THE IOWA MEDICAL SOCIETY, 1980, 70 (02): : 61 - &
[50] Extended Dosing Regimens for Fungal Prophylaxis
Lehrnbecher, Thomas
Bochennek, Konrad
Klingebiel, Thomas
Gastine, Silke
Hempel, Georg
Groll, Andreas H.
CLINICAL MICROBIOLOGY REVIEWS, 2019, 32 (03)

← 1 2 3 4 5 →